Health Products (Licensing of Retail Pharmacies) (Amendment) Regulations 2021

Status:

Published in Subsidiary Legislation Supplement
on 17 Feb 2021

No. S 106

Health Products Act

(CHAPTER 122D)

Health Products
(Licensing of Retail Pharmacies)
(Amendment) Regulations 2021

In exercise of the powers conferred by section 72(1) of the Health Products Act, the Health Sciences Authority, with the approval of the Minister for Health, makes the following Regulations:

Citation and commencement

1. These Regulations are the Health Products (Licensing of Retail Pharmacies) (Amendment) Regulations 2021 and come into operation on 1 March 2021.

Amendment of regulation 2

2. Regulation 2 of the Health Products (Licensing of Retail Pharmacies) Regulations 2016 (G.N. No. S 330/2016) (called in these Regulations the principal Regulations) is amended —

(a)

by inserting, immediately after the definition of “collaborative prescribing practitioner”, the following definition:

“ “CTGT product” means a health product categorised as a cell, tissue or gene therapy product in the First Schedule to the Act;”; and

(b)

by deleting the words “, to a person other than a qualified pharmacist at another retail pharmacy” in the definition of “telepharmacy services”.

Amendment of regulation 3

3. Regulation 3 of the principal Regulations is amended —

(a)

by inserting, immediately before the words “the prescription‑only medicine supplied” in paragraph (2)(b), the words “in the case of therapeutic products only,”;

(b)

by inserting, immediately after the words “therapeutic product” in the definition of “prescription‑only medicine” in paragraph (5), the words “or a CTGT product”;

(c)

by inserting, immediately after the words “Health Products (Therapeutic Products) Regulations 2016” in the definition of “valid prescription” in paragraph (5), the words “or regulation 2(2) of the Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (G.N. No. S 104/2021), as the case may be”; and

(d)

by inserting, immediately after paragraph (5), the following paragraph:

“(6) In relation to a collaborative prescribing practitioner mentioned in paragraphs (2)(a) and (3), references to prescription‑only medicine in paragraph (2)(a) and specified health product in paragraph (3) are references to a therapeutic product only.”.

Amendment of First Schedule

4. The First Schedule to the principal Regulations is amended by inserting, immediately after item 2, the following item:

“3. CTGT products”.

[G.N. Nos. S 120/2018; S 93/2019]

Made on 15 February 2021.

KANDIAH SATKUNANANTHAM

Chairman,
Health Sciences Authority,
Singapore.

[401:04/01-000; AG/LEGIS/SL/122D/2015/14 Vol. 1]

(To be presented to Parliament under section 72(5) of the Health Products Act).

Search within Legislation